Pharvaris to Present in Upcoming March Investor 2-03-2023, 19:00

BDR Solutions and Smile Digital Health Partner for Federal 28-02-2023, 21:31

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26